Dabrafenib and trametinib combination therapy safely performed in a patient with metastatic melanoma after severe liver toxicity due to vemurafenib

Shimada, Shuichi; Fukushima, Satoshi; Niimori, Daisuke; Miyashita, Azusa; Setoyama, Hiroko; Sasaki, Yutaka; Ihn, Hironobu

doi:10.1111/1346-8138.14206

Search citation statements

Order By: Relevance

Paper Sections

Select...

J O U R N a L P R E -P R O O F1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2018

2024

Publication Types

Select...

Article4

Relationship

Self Cite0

Independent4

Authors

Journals

Cited by 4 publications

(1 citation statement)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, patients developing erlotinib-related DILI were switched to gefitinib without DILI recurrence [99,112]. The dabrafenib/trametinib combination was also successfully introduced to a patient developing vemurafenib-induced severe liver injury [113].…”

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%

Multikinase inhibitor-induced liver injury in patients with cancer: A review for clinicians

Houron

Danielou

Mir

et al. 2021

Critical Reviews in Oncology/Hematology

View full text Add to dashboard Cite

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

show abstract

Section: J O U R N a L P R E -P R O O Fmentioning

confidence: 99%